Fremanezumab ( DrugBank: Fremanezumab )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 124 | 皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症 | 1 |
| 226 | 間質性膀胱炎（ハンナ型） | 1 |
124. 皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症
臨床試験数 : 12 / 薬物数 : 14 - (DrugBank : 5) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04334408 (ClinicalTrials.gov) | December 2021 | 2/4/2020 | Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL | A Phase II Double-Blinded Placebo Controlled Individual Subject Stepped Wedge Clinical Trial Evaluating the Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL | Cadasil;Migraine | Drug: Fremanezumab;Drug: Placebo | Mayo Clinic | NULL | Not yet recruiting | 18 Years | 70 Years | All | 5 | Phase 2 | United States |
226. 間質性膀胱炎（ハンナ型）
臨床試験数 : 143 / 薬物数 : 171 - (DrugBank : 56) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 145
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04447729 (ClinicalTrials.gov) | October 15, 2020 | 10/6/2020 | A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome | A Multicenter, Open-label Pilot Study of the Efficacy and Safety of Fremanezumab for Treatment of Female Patients With Interstitial Cystitis-Bladder Pain Syndrome | Interstitial Cystitis | Drug: fremanezumab | Teva Branded Pharmaceutical Products R&D, Inc. | NULL | Withdrawn | 18 Years | N/A | Female | 0 | Phase 2 | NULL |